{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T13:21:06Z","timestamp":1789132866336,"version":"build-2803163510"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2007,7,17]],"date-time":"2007-07-17T00:00:00Z","timestamp":1184630400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2007,12]]},"DOI":"10.1186\/1471-2334-7-79","type":"journal-article","created":{"date-parts":[[2007,7,17]],"date-time":"2007-07-17T18:13:22Z","timestamp":1184696002000},"source":"Crossref","is-referenced-by-count":4,"title":["Comparative antimicrobial susceptibility of aerobic and facultative bacteria from community-acquired bacteremia to ertapenem in Taiwan"],"prefix":"10.1186","volume":"7","author":[{"given":"Sai-Cheong","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shie-Shian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Wei","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Phone","family":"Fung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Bin","family":"Shieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LK","family":"Siu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,7,17]]},"reference":[{"key":"522_CR1","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1128\/AAC.45.6.1915-1918.2001","volume":"45","author":"PC Fuchs","year":"2001","unstructured":"Fuchs PC, Barry AL, Brown SD: In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 North American medical centers. Antimicrob Agents Chemother. 2001, 45: 1915-1918. 10.1128\/AAC.45.6.1915-1918.2001.","journal-title":"Antimicrob Agents Chemother"},{"key":"522_CR2","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1128\/AAC.45.6.1860-1867.2001","volume":"45","author":"DM Livermore","year":"2001","unstructured":"Livermore DM, Carter MW, Bagel S, Wiedemann B, Saquero F, Loza E, Endtz HP, Nguyen J, Nord CE, Struelens MJ, Nonhoff C, Turnidage J, Bell J, Zbinden R, Pfister S, Mixson L, Shungu DL: In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia. Antimicrob Agents Chemother. 2001, 45: 1860-1867. 10.1128\/AAC.45.6.1860-1867.2001.","journal-title":"Antimicrob Agents Chemother"},{"key":"522_CR3","first-page":"1","volume":"41","author":"JR Prous","year":"2005","unstructured":"Prous JR, Fairley L, Fleischer J: Ertapenam: the first group 1 carbapenem. Drugs Today. 2005, 41: 1-16.","journal-title":"Drugs Today"},{"key":"522_CR4","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1093\/jac\/dkg404","volume":"52","author":"PM Shah","year":"2003","unstructured":"Shah PM, Isaacs RD: Ertapenem, the first of a new group of carbapenems. J Antimicrob Chemother. 2003, 52: 538-542. 10.1093\/jac\/dkg404.","journal-title":"J Antimicrob Chemother"},{"key":"522_CR5","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1093\/jac\/dkg375","volume":"52","author":"DM Livermore","year":"2003","unstructured":"Livermore DM, Sefton AM, Scott GM: Properties and potential of ertapenem. J Antimicrob Chemother. 2003, 52: 331-344. 10.1093\/jac\/dkg375.","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl S2","key":"522_CR6","first-page":"ii23","volume":"53","author":"HM Wexler","year":"2004","unstructured":"Wexler HM: In vitro activity of ertapenem: review of recent studies. J Antimicrob Chemother. 2004, 53 (Suppl S2): ii23-ii28.","journal-title":"J Antimicrob Chemother"},{"key":"522_CR7","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/S0924-8579(02)00129-2","volume":"20","author":"NJ Hilliard","year":"2002","unstructured":"Hilliard NJ, Johnson CN, Armstrong SH, Quarles S, Waites KB: In vitro activity of ertapenem(MK-0826) against multi-drug resistant Streptococcus pneumoniae compared with 13 other antimicrobials. Int J Antimicrob Agent. 2002, 20: 136-140. 10.1016\/S0924-8579(02)00129-2.","journal-title":"Int J Antimicrob Agent"},{"key":"522_CR8","doi-asserted-by":"publisher","first-page":"2831","DOI":"10.1128\/AAC.45.10.2831-2837.2001","volume":"45","author":"DM Livermore","year":"2001","unstructured":"Livermore DM, Oakton KJ, Carter MW, Warner M: Activity of ertapenem (MK-0826) versus Enterobacteriaceae with potent-lactamases. Antimicrob Agents Chemother. 2001, 45: 2831-2837. 10.1128\/AAC.45.10.2831-2837.2001.","journal-title":"Antimicrob Agents Chemother"},{"key":"522_CR9","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1086\/339543","volume":"34","author":"OR Guillermo","year":"2002","unstructured":"Guillermo OR, Caballero-Lopez J, Friedland IR, Gail LW, Carides A: Study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults. Clin Infect Dis. 2002, 34: 1076-1083. 10.1086\/339543.","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"522_CR10","doi-asserted-by":"publisher","first-page":"S119","DOI":"10.1086\/341932","volume":"35","author":"EC Goldstein","year":"2002","unstructured":"Goldstein EC, Citron DM, Merriam CV, Warren Y, Tyrrell KL, Gesser RM: General microbiology and in vitro susceptibility of anaerobes isolated from complicated skin and skin-structure infections in patients enrolled in a comparative trial of ertapenem versus piperacillin-tazobactam. Activity of ertapenem in skin infections. Clin Infect Dis. 2002, 35 (Suppl 1): S119-S125. 10.1086\/341932.","journal-title":"Clin Infect Dis"},{"key":"522_CR11","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1086\/380488","volume":"37","author":"LA Mandell","year":"2003","unstructured":"Mandell LA, Bartlett JG, Dowell SF, File TM, Musher DM, Whitney C: Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Guidelines for CAP in adults. Clin Infect Dis. 2003, 37: 1405-1433. 10.1086\/380488.","journal-title":"Clin Infect Dis"},{"key":"522_CR12","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1086\/424846","volume":"9","author":"BA Lipsky","year":"2004","unstructured":"Lipsky BA, Berendt AR, Deery HG, Embil JM, Warren SJ, Karchmer AW, LeFrock JL, Lew DP, Mader JT, Norden C, Tan JS: Diagnosis and Treatment of Diabetic Foot Infections. Guidelines for diabetic foot infections. Clin Infect Dis. 2004, 9: 885-910. 10.1086\/424846.","journal-title":"Clin Infect Dis"},{"key":"522_CR13","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1089\/109629602762539535","volume":"3","author":"J Tellado","year":"2002","unstructured":"Tellado J, Woods GL, Gesser R, McCarroll K, Teppler H: Ertapenem versus piperacillin-tazobactam for treatment of mixed anaerobic complicated intra-abdominal, complicated skin and skin structure, and acute pelvic infections. Surg Infect. 2002, 3: 303-314. 10.1089\/109629602762539535.","journal-title":"Surg Infect"},{"key":"522_CR14","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1093\/jac\/dkh218","volume":"53","author":"A Alhambra","year":"2004","unstructured":"Alhambra1 A, Cuadros JA, Cacho J, G\u00f3mez-Garc\u00e9s JL, Al\u00f3s JI: In vitro susceptibility of recent antibiotic-resistant urinary pathogens to ertapenem and 12 other antibiotics. J Antimicrob Chemother. 2004, 53: 1090-1094. 10.1093\/jac\/dkh218.","journal-title":"J Antimicrob Chemother"},{"key":"522_CR15","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1089\/109629602761624171","volume":"3","author":"JE Mazuki","year":"2002","unstructured":"Mazuki JE, Sawyer RG, Nathens AB, Dipiro JT, Schein M, Kudsk KA, Yowler C: The surgical infection society guidelines on antimicrobial therapy for intra-abdominal infections. Surg Infect. 2002, 3: 161-173. 10.1089\/109629602761624171.","journal-title":"Surg Infect"},{"key":"522_CR16","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1086\/378702","volume":"37","author":"JS Solomkin","year":"2003","unstructured":"Solomkin JS, Mazuski JE, Baron EJ, Sawyer RG, Nathens AB, DiPiro JT, Buchman T, Dellinger EP, Jernigan J, Gorbach S, Chow AW, Bartlett J: Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Treatment guidelines for intra-abdominal infections. Clin Infect Dis. 2003, 37: 997-1005. 10.1086\/378702.","journal-title":"Clin Infect Dis"},{"key":"522_CR17","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1128\/AAC.46.9.2895-2900.2002","volume":"46","author":"KM Tomera","year":"2002","unstructured":"Tomera KM, Burdmann EA, Reyna OGP, Jiang Q, Wimmer WM, Woods GL, Richard M: Ertapenem versus ceftriaxone followed by appropriate oral therapy for treatment of complicated urinary tract infections in adults. Antimicrob Agents Chemother. 2002, 46: 2895-2900. 10.1128\/AAC.46.9.2895-2900.2002.","journal-title":"Antimicrob Agents Chemother"},{"key":"522_CR18","first-page":"M7","volume-title":"CLSI (formerly NCCLS)","author":"MA Wikler","year":"2006","unstructured":"Wikler MA, Low DE, Cockerill FR, Sheehan DJ, Craig WA, Tenover FC, Dudley MN: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically:approved standard-seventh edition. CLSI (formerly NCCLS). 2006, M7-A7."},{"key":"522_CR19","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1128\/JCM.31.10.2683-2688.1993","volume":"31","author":"MB Huang","year":"1993","unstructured":"Huang MB, Gay TE, Baker CN, Bannerjee SN, Tenover FC: Two per cent sodium chloride is required for susceptibility testing of staphylococci with oxacillin when using agar-based dilution methods. J Clin Microbiol. 1993, 31: 2683-2688.","journal-title":"J Clin Microbiol"},{"key":"522_CR20","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1128\/AAC.33.11.1869","volume":"33","author":"A Tomasz","year":"1989","unstructured":"Tomasz A, Drugeon HB, de Lencastre HM, Jabes D, McDougal L, Bille J: New mechanism for methicillin resistance in Staphylococcus aureus:clinical isolates that lack the PBP 2a gene and contain normal penicillin-binding capacity. Antimicrob Agents Chemother. 1989, 33: 1869-1874.","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"522_CR21","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1128\/JCM.30.7.1728-1733.1992","volume":"30","author":"K Ubukata","year":"1992","unstructured":"Ubukata K, Nakagami S, Nitta A, Yamane A, Kawakami S, Sugiura M, Konno A: Rapid detection of the mecA gene in methicillin-resistant staphylococci by enzymatic detection of polymerase chain reaction products. Clin Microbiol. 1992, 30 (7): 1728-1733.","journal-title":"Clin Microbiol"},{"key":"522_CR22","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1592\/phco.25.1.74.55620","volume":"25","author":"MJ Rybak","year":"2005","unstructured":"Rybak MJ, LaPente KL: Community-associated methicillin-resistant Staphylococcus aureus: a review. Pharmacother. 2005, 25: 74-85. 10.1592\/phco.25.1.74.55620.","journal-title":"Pharmacother"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2334-7-79\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-7-79.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-7-79","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-7-79.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,25]],"date-time":"2020-04-25T04:59:53Z","timestamp":1587790793000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/1471-2334-7-79"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7,17]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["522"],"URL":"https:\/\/doi.org\/10.1186\/1471-2334-7-79","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,7,17]]},"article-number":"79"}}